Srikonda Sastry

This inventor holds 3 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Xenoport, Inc.. Active years: 2014-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srikonda Sastry. Retrieved from https://idiyas.com/inventor/srikonda-sastry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 5.0

ph-index = 1

Company Filing History:

3 out of 142

Xenoport, Inc.

patents

Years Active: 2014-2018

Loading Chart...

3 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9949941 - GABA analog prodrug sustained release oral dosage forms (2018-04-24),

2. 8906412 - GABA analog prodrug sustained release oral dosage forms (2014-12-09),

3. 8795725 - GABA analog prodrug sustained release oral dosage forms (2014-08-05),

Title: Srikonda Sastry: Innovator in Pharmaceutical Formulations

Introduction

Srikonda Sastry is a notable inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of sustained release oral dosage forms. With a total of 3 patents, his work has the potential to impact the treatment of various diseases and disorders.

Latest Patents

Sastry's latest patents include innovative formulations such as the GABA analog prodrug sustained release oral dosage forms. These formulations involve a gabapentin prodrug, specifically 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid. The dosage forms are designed to be effective in treating or preventing diseases and disorders for which gabapentin is therapeutically beneficial.

Career Highlights

Srikonda Sastry is currently associated with Xenoport, Inc., where he continues to advance his research and development efforts. His expertise in pharmaceutical sciences has led to the creation of innovative solutions that enhance drug delivery and efficacy.

Collaborations

Some of his notable coworkers include Kenneth C Cundy and Manshiu Leung. Their collaborative efforts contribute to the innovative environment at Xenoport, Inc., fostering advancements in pharmaceutical technology.

Conclusion

Srikonda Sastry's work exemplifies the importance of innovation in the pharmaceutical industry. His contributions through patents and collaborations are paving the way for improved therapeutic options.

Profile summary based on public USPTO records.